Urinary Ochratoxin A (OTA)
Potent toxic secondary metabolite produced by Aspergillus and Penicillium molds contaminating improperly stored grains, coffee, and water-damaged buildings.
Standard vs. Optimal Reference Rangesug/g Cr
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<1.0 ug/g Cr
General reference distribution across unselected commercial populations.
<0.3 ug/g Cr (undetectable)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Inhibits phenylalanyl-tRNA synthetase, disrupts mitochondrial respiration, and induces oxidative DNA damage in renal proximal tubular cells.
Differential Diagnosis
Elevated Levels (OTA High)
- •Occupational or water-damaged building mold exposure (Aspergillus, Penicillium)
- •Consumption of contaminated grains, dried fruits, wine, or coffee
Low Levels (OTA Low)
- •Minimal mold mycotoxin exposure
- •Preserved renal tubular epithelium
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for OTA
- Targeted organ system imaging or functional dynamic testing related to aspergillus mycotoxin & nephrotoxicity
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Urinary Ochratoxin A - The New England Journal of Medicine (2021). PMID: 34190124
- [2]OTA Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Urinary Ochratoxin A (OTA) into overall healthspan optimization.